May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Clinical Comparison of Healon5 and Healon in Phacoemulsification and Intraocular Lens Implantation: A Randomized Multicenter Study
Author Affiliations & Notes
  • T. Okazaki
    Dept Ophthalmology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
  • T. Oshika
    Dept Ophthalmology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
  • S. Eguchi
    Eguchi Eye Hospital, Hokkaido,
  • K. Oki
    Oki eye clinic, Tokyo,
  • S. Yaguchi
    Dept Ophthalmology, Showa University School of Medicine, Kanagawa,
  • H. Bissen-Miyajima
    Tokyo Dental College Suidobashi Hospital, Tokyo,
  • I. Ota
    Dept Ophthalmology, Miyake Eye Hospital, Aichi,
  • G. Sugita
    Sugita Eye Hospital, Aichi,
  • K. Miyata
    Miyata Eye Hospital, Miyazaki,
  • Footnotes
    Commercial Relationships  T. Okazaki, None; T. Oshika, None; S. Eguchi, None; K. Oki, None; S. Yaguchi, None; H. Bissen-Miyajima, None; I. Ota, None; G. Sugita, None; K. Miyata, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 196. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Okazaki, T. Oshika, S. Eguchi, K. Oki, S. Yaguchi, H. Bissen-Miyajima, I. Ota, G. Sugita, K. Miyata; Clinical Comparison of Healon5 and Healon in Phacoemulsification and Intraocular Lens Implantation: A Randomized Multicenter Study . Invest. Ophthalmol. Vis. Sci. 2003;44(13):196.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the ophthalmic viscosurgical devices (OVDs), Healon5 (viscoadaptive; dispersive and cohesive) and Healon (cohesive), in terms of their overall clinical performance during phacoemulsification and intraocular lens (IOL) implantation as well as their influence on intraocular pressure (IOP) and corneal endothelium. Methods: In this randomized prospective clinical study, the performance of Healon5 (sodium hyaluronate 2.3%) and Healon (sodium hyaluronate 1.0%) was evaluated during cataract surgery in 157 patients (Healon5; 79, Healon; 78). Surgeons evaluated on a 5-point scale; retention during phacoemulsification (primary endpoint), ease of injection, maintenance of anterior chamber during continuous curvilinear capsulorhexis (CCC), facilitation of IOL of implantation, ease of removal from the eye, and transparency during surgery. The IOP was measured preoperatively and 5 hours, 24 hours, 7days, and 3 months postoperatively. The corneal thickness was measured before and 24 hours, 7 days, and 3 month after surgery. Corneal endothelial cell count was recorded preoperatively and 3months postoperatively. Results: Intraocular retention during phacoemulsification was assessed as good or very good in 77% of the Healon5 group compared to 8% of the Healon group, which were statistically significant (p<.0001, Wilcoxon rank-sum test). The Healon5 group showed significantly better scores for maintenance of the anterior chamber during CCC (p<.0001) and facilitation of IOL implantation (p=.032), while Healon was assessed to be superior to Healon5 in terms of ease of injection (p<.0001), ease of removal from the eye (p<.0001), and transparency during surgery (p=.023). There were no statistically significant between-group differences in IOP changes, corneal endothelial cell count, and corneal thickness. Conclusions: Healon5 was rated to be better than Healon in terms of retention during phacoemulsification, maintenance of anterior chamber during CCC, and facilitation of IOL Implantation. Healon was assessed to be easier to remove. Both OVDs showed no differences in safety-related parameters. These findings indicate the efficacy of Healon5 in cataract surgery.

Keywords: cataract • anterior chamber 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×